# Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

> **NCT00513474** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 46 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporin-A
- **DRUG:** etoposide
- **DRUG:** methotrexate
- **DRUG:** rasburicase
- **DRUG:** sirolimus
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** total-body irradiation
- **DRUG:** fludarabine
- **DRUG:** allopurinol

## Key facts

- **NCT ID:** NCT00513474
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2013-02-12
- **Final completion:** 2013-02-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513474, "Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00513474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*